RESULTS	Valsartan had a significant beneficial effect on the least-square mean change in overall MLWHF score from baseline to study endpoint ( + / - standard error ) ( average followup 23.0 months ) compared with placebo ( 0.19 + / - 0.47 versus 1.94 + / - 0.48 ; P = .005 respectively ) .\